Bayer expands Kerendia heart failure program to 15,000 patients as it plans to start three Phase III trials

Bay­er is work­ing on ex­pand­ing the la­bel for its chron­ic kid­ney dis­ease drug Keren­dia, an­nounc­ing three new tri­als to in­ves­ti­gate it as a treat­ment for heart fail­ure.

MOON­RAK­ER will add 9,000 new pa­tients, ex­pand­ing the clin­i­cal de­vel­op­ment pro­gram to about 15,000 par­tic­i­pants and mak­ing it one of the largest heart fail­ure study pro­grams, Bay­er claims. CPC Clin­i­cal Re­search, a non-prof­it aca­d­e­m­ic re­search or­ga­ni­za­tion af­fil­i­at­ed with the Uni­ver­si­ty of Col­orado, is con­duct­ing the Bay­er-fund­ed tri­als with oth­er in­sti­tu­tions.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.